Thomas Chateau - Publications

Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUST.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: February 27, 2025

Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study.

Journal: Digestive diseases and sciences

Published: July 30, 2024

Prevalence of and Factors Associated with Respiratory Symptoms Among Patients with Inflammatory Bowel Disease: A Prospective Study.

Journal: Inflammatory bowel diseases

Published: November 29, 2021

Correction to: Crohn's Disease Only Visible on Small Bowel Capsule Endoscopy: A New Entity.

Journal: Digestive diseases and sciences

Published: September 25, 2020

Crohn's Disease Only Visible on Small Bowel Capsule Endoscopy: A New Entity.

Journal: Digestive diseases and sciences

Published: June 05, 2020

Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?

Journal: Journal of clinical medicine

Published: April 30, 2020

Surgery for Crohn's disease during pregnancy: A nationwide survey.

Journal: United European gastroenterology journal

Published: April 25, 2020

Thiopurines in inflammatory bowel disease: what's new ?

Journal: La Revue du praticien

Published: April 03, 2020

Evolving therapeutic goals in Crohn's disease management.

Journal: United European gastroenterology journal

Published: March 28, 2020

Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease.

Journal: Alimentary pharmacology & therapeutics

Published: February 01, 2020

Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.

Journal: The American journal of gastroenterology

Published: December 07, 2019

Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks.

Journal: Inflammatory bowel diseases

Published: November 27, 2019